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Objectives: We evaluated the treatment outcome in late acute (LA) periprosthetic joint infections (PJI) 
treated with debridement and implant retention (DAIR) versus implant removal. 
Methods: In a large multicenter study, LA PJIs of the hip and knee were retrospectively evaluated. Failure 
was defined as: PJI related death, prosthesis removal or the need for suppressive antibiotic therapy. LA 
PJI was defined as acute symptoms < 3 weeks in patients more than 3 months after the index surgery 
and with a history of normal joint function. 
Results: 445 patients were included, comprising 340 cases treated with DAIR and 105 cases treated with 
implant removal (19% one-stage revision ( n = 20), 74.3% two-stage revision ( n = 78) and 6.7% definitive 
implant removal ( n = 7). Overall failure in patients treated with DAIR was 45.0% (153/340) compared to 
24.8% (26/105) for implant removal ( p < 0.001). Difference in failure rate remained after 1:1 propensity- 
score matching. A preoperative CRIME80-score ≥3 (OR 2.9), PJI caused by S. aureus (OR 1.8) and implant 
retention (OR 3.1) were independent predictors for failure in the multivariate analysis. 
Conclusion: DAIR is a viable surgical treatment for most patients with LA PJI, but implant removal should 
be considered in a subset of patients, especially in those with a CRIME80-score ≥3. 
© 2019 The British Infection Association. Published by Elsevier Ltd. All rights reserved. 
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Introduction 
A periprosthetic joint infection (PJI) is a serious complica-
tion after joint arthroplasty and is accompanied by increased
morbidity and mortality. 1,2 Clinical outcome is highly dependent
on host related factors, clinical characteristics, the causative mi-
croorganism, and the applied antimicrobial therapy and surgical
techniques. 4 , 10 , 11 Therefore, optimizing treatment and composing
tailored strategies are crucial to improve clinical outcome. We
recently demonstrated that late acute PJIs have a relatively high
failure rate when treated with surgical debridement and implant
retention (DAIR). 21 Failure seems to be most prominent when the
infection is caused by Staphylococcus aureus , with reported failures
of around 50%, which is higher than described for early acute/post-
surgical PJIs. 13 , 17 , 19–21 Moreover, several preoperative variables,
defined according to the CRIME80-score (i.e. C -reactive protein
> 150 mg/L, C hronic obstructive pulmonary disease, R heumatoid
arthritis, fracture as I ndication for the prosthesis, M ale gender, not
E xchanging the mobile components during debridement and an
age above 80 years), expose patients to a higher failure risk as
well. 21 Despite the relatively high failure rate, a DAIR procedure is
still recommended as the first line surgical approach for all acute
PJIs if the implant is well fixed and if anti-biofilm antibiotics can
be applied. 15 However, revision of the prosthetic implant might be
a better treatment modality in a subset of patients with late acute
infections. 17 For this reason, we compared the clinical outcome of
patients with a late acute PJI treated with DAIR or immediate im-
plant removal in a large multicenter observational cohort study
and identified those patients who may benefit more from implant
removal instead of DAIR. Propensity score matching was applied to
correct for selection bias between both surgical techniques. 
Material and methods 
Study design and inclusion criteria 
We performed an international multicenter retrospective obser-
vational study in which data of all consecutive patients with a late
acute PJI of the hip or knee between January 2005 and Decem-
ber 2015 were collected. If centers were not able to provide cases
during the complete study period, a minimum of at least 10 con-
secutive cases was required to participate in the study. Late acute
PJI was defined as patients with a history of normal joint function
and who developed a sudden onset of symptoms and signs of a PJI,
such as acute pain and/or swelling of the prosthetic joint. Patients
with symptoms existing for longer than 3 weeks before surgical
treatment was applied, patients who were within 3 months afterhe index arthroplasty, patients with a sinus tract and patients in
hom antibiotic suppressive therapy was prescribed after surgery
or other reasons than persistent signs of infection (e.g. because
his was routine practice of the participating hospital and/or be-
ause the patient had severe comorbidity and was therefore, not
ligible for future surgeries) were excluded from the analysis. PJI
as defined according to the diagnostic criteria described by the
usculoskeletal Infection Society (MSIS). 16 Multiple variables on
atient characteristics, clinical presentation, microbiology results,
urgical and antibiotic treatment and outcome were collected and
nalyzed. Patients treated with DAIR comprised the same cohort as
escribed in our previous study. 21 Informed consent was retrieved
hen required by the ethics committee of the participating center.
linical outcome 
Failure was defined as: (i) the need for prosthesis removal due
o persistent or recurrent signs of infection in the DAIR group or
emoval of the revised prosthesis in the removal group (ii) the
eed for suppressive antibiotic therapy because of persistent clin-
cal or biochemical signs of infection, (iii) death due to the infec-
ion. The need for additional surgical debridement or spacer ex-
hange in case of two-stage revisions was not considered as fail-
re, but as part of the procedure. Complete remission was defined
s a functional implant at the last follow-up, which was defined
s the ability to walk without pain and the absence of clinical or
iochemical signs of persistent infection. 
ebridement and implant retention versus implant removal 
The surgical techniques of the DAIR procedure, one-stage and
wo-stage revision surgery are extensively described in litera-
ure. 3 , 10 In brief, in case of a DAIR procedure, visibly infected and
ecrotic tissue is excessively debrided, the wound is thoroughly ir-
igated using three to six liters of saline and mobile components
re exchanged if possible. The same holds for a one-stage proce-
ure, with the addition that the whole prosthesis is removed and
xchanged for a new implant. Subsequent antimicrobial therapy is
rescribed for a minimum of six weeks, but a duration of three
onths of antibiotics is most often applied for both procedures.
uring a two-stage procedure, the prosthesis is removed in the
rst stage and in most cases temporarily replaced by a cemented
pacer loaded with antibiotics. Subsequent antimicrobial therapy is
rescribed for a minimum of six weeks. In the second surgery, the
ew prosthesis is reimplanted during or after finishing antibiotic
herapy for the initial infection. The applied antibiotic regimens in
his study are depicted in Supplementary Table 1. 
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Table 1 
Patient characteristics late acute prosthetic joint infection (PJI) treated with surgical debridement and implant retention (DAIR) [ n = 340] versus implant removal [ n = 105 
(1-stage revision ( n = 20), 2-stage revision ( n = 78) or definitive removal of the implant ( n = 7)]. 
Total patient group Propensity score matching 1:1 
Implant retention 
( n = 340) 
Implant removal 
( n = 105) 
p -value Implant retention 
( n = 81) 
Implant removal 
( n = 81) 
p -value 
Baseline characteristics 
Gender, male 51.5% (175/340) 42.9% (45/105) 0.12 50.6% (41/81) 42.0% (34/81) 0.27 
Age > 80 years c 21.5% (73/340) 20.0% (21/105) 0.75 19.8% (16/81) 22.2% (18/81) 0.70 
BMI > 30 48.9% (110/225) 41.8% (28/67) 0.31 50.0% (25/50) 41.2% (21/51) 0.37 
ASA classification ≥ III 48.6% (140/288) 44.4% (36/81) 0.51 47.1% (33/70) 42.6% (26/61) 0.60 
Medical history 
Hypertension 59.6% (202/339) 61.9% (65/105) 0.67 64.2% (52/81) 61.7% (50/81) 0.67 
Ischemic heart disease 12.1% (41/340) 8.6% (9/105) 0.32 8.6% (7/81) 7.4% (6/81) 0.77 
Heart failure 9.1% (31/339) 6.7% (7/105) 0.43 2.5% (2/81) 3.7% (3/81) 0.65 
Diabetes Mellitus 25.0% (85/340) 22.9% (24/105) 0.58 17.3% (14/81) 22.2% (18/81) 0.43 
COPD c 10.0% (34/340) 14.3% (15/105) 0.22 4.9% (4/81) 13.6% (11/81) 0.06 
Chronic renal insufficiency 7.6% (26/340) 11.4% (12/105) 0.23 6.2% (5/81) 6.2% (5/81) 1.0 
Liver cirrhosis 3.2% (11/340) 6.7% (7/105) 0.12 6.2% (5/81) 3.7% (3/81) 0.47 
Active malignancy 8.5% (29/340) 2.9% (3/105) 0.05 2.5% (2/81) 3.7% (3/81) 0.65 
Rheumatoid arthritis c 7.9% (27/340) 5.7% (6/105) 0.45 8.6% (7/81) 7.4% (6/81) 0.77 
Medication 
Oral anticoagulant 18.2% (61/336) 10.7% (11/103) 0.07 16.0% (13/81) 8.9% (7/79) 0.17 
Immune-suppressive drugs 11.5% (39/340) 7.6% (8/105) 0.26 11.1% (9/81) 9.9% (8/81) 0.80 
Characteristics infected implant 
Knee 72.6% (247/340) 57.1% (60/105) 0.003 65.4% (53/81) 61.7% (50/81) 0.62 
Indication prosthesis: fracture c 5.4% (17/313) 6.9% (7/101) 0.58 5.4% (4/81) 9.1% (7/81) 0.38 
Revision prosthesis 28.4% (96/338) 32.4% (33/102) 0.44 30.9% (25/81) 31.6% (25/79) 0.92 
Tumor prosthesis 4.3% (14/326) 4.9% (5/103) 0.81 3.9% (3/76) 3.8% (3/79) 0.96 
Cemented stem 75.3% (186/247) 58.3% (49/84) 0.003 70.7% (41/58) 60.6% (40/66) 0.24 
Age of the implant > 2 years 63.5% (216/340) 61.9% (65/281) 0.76 53.1% (43/81) 60.5% (49/81) 0.34 
Clinical presentation 
Duration of symptoms > 10 days 20.9% (71/340) 30.5% (32/105) 0.04 22.2% (18/81) 18.4% (23/81) 0.37 
Temperature > 38.5 °C 21.3% (70/329) 5.9% (6/101) < 0.001 16.9% (13/77) 6.5% (5/77) 0.05 
Physical signs of inflammation 81.5% (264/324) 79.4% (81/102) 0.64 79.7% (59/74) 79.5% (62/78) 0.97 
CRP > 150 mg/L c 60.4% (194/321) 53.2% (50/94) 0.21 60.0% (45/75) 59.2% (42/71) 0.92 
Leucocytes > 17 cells/μL 14.5% (46/317) 17.3% (18/104) 0.49 21.1% (16/76) 15.0% (12/80) 0.33 
Bacteremia a 32.2% (109/339) 30.5% (32/105) 0.75 32.1% (26/81) 30.9% (25/81) 0.87 
Endocarditis 3.8% (13/340) 3.8% (4/105) 1.0 2.5% (2/81) 2.5% (2/81) 1.0 
Source identified 45.9% (156/340) 33.7% (35/104) 0.03 37.0% (30/81) 38.8% (31/80) 0.82 
Identified micro-organism 
Staphylococcus aureus 41.5% (141/340) 43.8% (46/105) 0.67 43.2% (35/81) 43.2% (35/81) 1.0 
– Methicillin resistant 5.6% (19/340) 8.6% (9/105) 0.27 7.4% (6/81) 7.4% (6/81) 1.0 
Enterococcus species 3.2% (11/340) 8.6% (9/105) 0.02 3.7% (3/81) 9.9% (8/81) 0.12 
Streptococcus species 28.5% (97/340) 16.2% (17/105) 0.01 25.9% (21/81) 16.0% (13/81) 0.12 
Gram negative rods 14.7% (50/340) 11.4% (12/105) 0.40 14.8% (12/81) 12.3% (10/81) 0.65 
Outcome 
Overall failure 45.0% (153/340) 24.8% (26/105) < 0.001 51.9% (42/81) 25.9% (21/81) 0.001 
Failed cases 
– Need for implant removal 35.9% (55/153) 30.8% (8/26) 0.61 43.9% (18/42) 38.1% (8/21) 0.66 
– Relapse of infection during FU 33.3% (51/153) 11.5% (3/26) 0.03 29.3% (12/42) 9.5% (2/21) 0.08 
– Reinfection during FU 7.8% (12/153) 38.5% (10/26) < 0.001 12.2% (5/42) 42.9% (9/21) 0.006 
– Need for suppressive therapy 15.7% (24/153) 0% (0/26) 0.03 9.8% (4/42) 0.0% (0/21) 0.14 
– Death due to PJI 7.2% (11/153) 19.2% (5/26) 0.05 4.9% (2/42) 9.5% (2/21) 0.48 
Overall PJI related death 3.2% (11/340) 4.8% (5/105) 0.52 2.5% (2/81) 2.5% (2/81) 1.0 
Complete remission in non-failures b 86.1% (155/180) 84.3% (64/75) 0.87 81.1% (30/37) 87.5% (49/56) 0.40 
a Patients in whom no blood cultures were obtained were considered as blood culture negative cases. 
b Defined as: patients with a retained and pain-free implant at the last follow-up. 
c Preoperative risk factors for failure in late acute PJI according to the CRIME80 score (6). BMI: Body Mass Index, ASA: American Society of Anesthesiologist, COPD: Chronic 
Obstructive Pulmonary Disease, CRP: C-Reactive Protein. 
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m  tatistical analysis 
A Chi-square test (or a Fisher exact-test when appropriate)
as used to analyze the difference between groups for categorical
ariables, and a student t -test (or Mann Witney U test when data
as not normally distributed) for continuous variables. A Kaplan
eier survival curve with a Cox-regression analysis was used
o evaluate failure rate in time. To correct for bias between the
AIR group versus the implant removal group, a propensity score
atching was performed. A propensity score was calculated using
 logistic regression model in which the surgical strategy was used
s the dependent variable, and variables that were significantly
ifferent between the implant retention group and the implantemoval group as covariates. Matching was performed using a
aliper of two decimals, and identical scores were randomized to
erform the matching. Chi-square testing was performed to ana-
yze the difference in outcome between both surgical approaches
implant retention versus implant removal). Univariate analysis
sing Pearson correlation was performed for determining risk
actors for failure. Variables with a significance level of < 0.2 were
nalyzed in a binary multivariate logistic regression model. The
ropensity score for DAIR was included in the model. For all anal-
ses, p -values < 0.05 were considered as statistically significant.
ll analyses were two-tailed. Data were presented as mean ±
tandard Deviation (SD) when data was normally distributed or
edian ± Inter Quartile Range (IQR) when data was not normally
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Table 2 
CRIME80-score, pre-operative risk score for predicting DAIR failure in late acute 
periprosthetic joint infections. 
CRIME80-score 
Variable Description Score 
C COPD 2 
CRP > 150 mg/L 1 
R Rheumatoid Arthritis 3 
I Index surgery (prosthesis indicated for a fracture) 3 
M Male gender 1 
E Exchange of mobile components −1 
80 Age > 80 years 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Failure rate late acute PJI in patients with a high versus low CRIME80-score 
(depicted in Table 2 ) according to the surgical strategy. 
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p  distributed. Statistical analysis was performed using SPSS, version
23.0 (SPSS Inc., Chicago, IL). 
Results 
Patient characteristics implant retention versus implant removal 
A total of 445 patients from 27 centers were included in the
analysis. Table 1 shows the preoperative differences between pa-
tients with late acute PJI treated with DAIR and implant reten-
tion ( n = 340) versus patients in whom the implant was removed
( n = 105). In the implant removal group, one-stage revision was
performed in 20 cases (19.0%), two-stage revision in 78 cases
(74.3%), and definitive implant removal in 7 cases (6.7%) (Girdle-
stone for hips [ n = 5] and arthrodesis for knees [ n = 2]). Compared
to implant removal, debridement with implant retention was per-
formed more often in knee PJIs, cemented prostheses and in pa-
tients presenting with fever, a duration of symptoms for less than
10 days and with an identified source of infection. Factors associ-
ated with worse outcome in late acute PJIs, like S. aureus infections
and preoperative risk factors predictive for failure according to the
CRIME80-score ( Table 2 ; including C-reactive protein and chronic
obstructive pulmonary disease (C), rheumatoid arthritis (R), frac-
ture as indication for the prosthesis (I), male gender (M), not ex-
changing the mobile components during DAIR (E), and age above
80 years (80) 21 ) were similar between both groups. 
Clinical outcome implant retention versus implant removal 
Table 1 shows the clinical characteristics and failure rate in the
implant retention and implant removal group. The overall failure
in patients treated with DAIR was 45.0% (153/340) versus 24.8%
(26/105) in patients treated with implant removal ( p < 0.001).
There was no difference in failure rate between one-stage versus
two-stage revision surgery: 25.0% (5/20) versus 24.4% (19/78), re-
spectively ( p 0.95). The higher failure rate in the implant retention
group was dominated by the need for suppressive therapy because
of persistent signs of infection and a relapse of infection during
follow-up, while most of the failures in the implant removal group
were due to a reinfection with another microorganism and PJI re-
lated death. The absolute number of PJI related death did not dif-
fer between both groups: 3.2% (11/340) for the implant retention
group versus 4.8% (5/105) for the implant removal group, ( p 0.52).
The need for prosthesis removal as a primary endpoint for failure
was the same in both groups. The higher failure rate in the implant
retention group remained after propensity score matching for all
significantly different variables between both groups as depicted
in Table 1 . We additionally performed a multivariate analysis in-
cluding all variables with a p -value < 0.2 in the univariate analysis
predictive for failure (i.e. the propensity score for DAIR, CRIME80-
score ≥ 3, endocarditis, bacteremia, fever, < 1 year after the index
surgery, use of immune suppressive drugs and S. aureus PJI). A pre-
operative CRIME80-score ≥ 3 (OR 2.9, 95% CI 1.7–4.9, p < 0.001), aJI caused by S. aureus (OR 1.8, 95% CI 1.1–2.9, p 0.03) and implant
etention (OR 3.1, 95% CI 1.7–5.8, p < 0.001) were the only sig-
ificant independent predictors for failure. Although the exchange
f mobile components during DAIR showed a significant decrease
n failure rate from 52.4% (77/147) to 36.4% (64/176) ( p 0.004), it
emained significantly higher compared to implant removal (24.8%
26/105) p 0.04). 
To assess whether the outcome of patients from centers with
 high case load differed from the ones with a lower case load,
e subdivided centers into 3 groups according to the number of
ases they provided: (i) less than 10 cases; (ii) between 10 and
0 cases; (iii) more than 20 cases. 5 centers provides less than 10
18.5%), 10 centers between 10 and 20 (37.5%) and 12 center more
han 20 cases (44%). Overall failure rates were 33.3% (12/36), 38.4%
38/99) and 41.6% (129/310), respectively ( p 0.58). Failure rates of
AIR were 47.5% (10/21), 45.2% (28/62) and 44.7% (115/257), re-
pectively ( p 0.97). 
ailure rates according to the preoperative CRIME80-score 
Fig. 1 shows the failure rate of patients treated with implant
etention and implant removal according to the CRIME80-score, 21 
 scoring system that includes several host factors and that can
e applied to decide which surgical treatment is preferred when
he microorganism is not known prior to surgery. For cases treated
ith implant removal, the variable ‘ E ’ (Exchanging the mobile com-
onents) was not taken into account to calculate the score. Vari-
bles included in the score were complete in 395 out the 445 cases
88.8%). A high preoperative risk score for DAIR failure defined by
 CRIME80-score ≥3, demonstrated a failure rate of 67.9% (53/78)
n the DAIR group and a 16.7% failure rate (4/24) in the implant re-
oval group ( p < 0.0 0 01). No significant difference in failure was
bserved with a CRIME80-score < 3 (35.8% (78/218) versus 23.9%
16/67), respectively ( p 0.07). 
ailure rates according to the microorganism causing the infection 
nd the possibility to exchange the mobile components 
Fig. 2 shows the failure rate in time between the different sur-
ical strategies and causative microorganisms. The overall median
ollow-up of non-failures was 34 months (IQR 15–55) in the im-
lant retention group versus 20 months (IQR 10–40) in the im-
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Fig. 2. Outcome late acute PJI caused by S. aureus (A) and other microorganisms (B), knees (C) and hips (D) according to the surgical strategy. Survival is defined as treatment 
success, as described in the material and method section. 
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c  lant removal group ( p 0.27). For PJI caused by microorganisms
ther than S. aureus , failure rate was 38.7% (77/199) in the im-
lant retention group versus 23.7% (14/59) in the implant removal
roup ( p 0.04). In the implant retention group, the exchange of
obile components during debridement showed a decrease in fail-
re rate from 47.0% (39/83) to 29.6% (32/108) ( p 0.01). When mo-
ile components were exchanged, implant removal did not show
ny significant benefit in these cases (failure rate 29.6% (32/108)
ersus 23.7% (14/59), respectively, p 0.41). For PJI caused by S. au-
eus , failure rate was 53.9% (76/141) in the implant retention group
ersus 26.1% (12/46) in the implant removal group ( p 0.001). The
ddition of rifampin in S. aureus PJI decreased failure rates from
5.2% (15/23) to 50.4% (57/113) ( p 0.20). In patients with S. au-
eus PJI in whom the mobile components were exchanged had a
ailure rate of 47.1% (32/68) ( p 0.02, compared to implant removal
6.1% (12/46)), and further decreased to 36.6% (15/41) when pa-
ients were subsequently treated with a fluoroquinolone in com-
ination with rifampin. Within this group, failure rate was not
tatistically significantly different compared to implant removal
36.6% versus 26.1%, p 0.29). The difference between failure rates
ccording to the surgical strategy was the same for hips and knees
 Fig. 2 (c) and (d)). 
roposed surgical treatment algorithm 
Based on our analyses, we propose a surgical treatment al-
orithm based on the CRIME80-score, the microorganism causing
he infection and its susceptibility pattern (when available prior to
urgery) to decide whether revision surgery instead of a DAIR pro-
edure should be considered as first surgical treatment approach
 Fig. 3 ). According to this algorithm, a DAIR procedure is advised
hen the failure rate of DAIR is ≤ 50%, revision surgery should
e considered if the failure rate of DAIR is > 50–65%, and re-
ision surgery is advised when the failure rate of DAIR exceeds
5%. Because the microorganism causing the infection is mostly
ot known prior to surgery, we first subdivided patients accord-
ng to their preoperative risk score for DAIR failure ( Table 2 ). How-
ver, if the microorganism and its susceptibility to antibiotics are
dentified, a DAIR procedure maybe a viable treatment option in an
dditional subset of patients, especially in those infections causedy S. aureus in whom the mobile components can be exchanged
nd an antibiotic regimen of rifampin plus a fluoroquinolone can
e administered ( Fig. 3 ). 
unctional outcome in non-failures 
Complete remission with a pain-free implant at the last point
f follow-up was achieved in 85.9% of the non-failures. In the non-
ailure group, there was no difference in complete remission be-
ween the implant retention group and the implant removal group
 Table 1 ). From the patients in the implant retention group who
ailed debridement and finally needed revision surgery ( n = 55),
ollow-up data was available in 41 cases (74.5%). During the last
ollow-up visit, 63.4% of these cases (26/41) had complete remis-
ion with a pain-free implant, while this was 84.3% (64/75) for
atients in whom revision surgery was applied as a first surgical
pproach ( p 0.007). There was no difference in functional outcome
fter revision surgery between cemented and uncemented prosthe-
es (pain-free implant in 82.9% (29/35) versus 89.7% (26/29), re-
pectively, p 0.44)). 
iscussion 
Current international guidelines still recommend a DAIR proce-
ure for all acute PJIs when the implant is well fixed and an an-
ibiotic regimen potent against biofilm infection can be adminis-
ered. 15 However, it is important to identify patients who have a
igh risk for DAIR failure prior to surgery in order to select the best
urgical option. In line with this, using the same cohort of patients,
e recently defined a preoperative risk score (CRIME80-score) to
dentify such high-risk patients for late acute PJIs. 21 Our current
ata suggests that patients with a CRIME80 score ≥ 3 (compris-
ng 21% of the total cohort) will probably benefit more from re-
ision surgery than from DAIR. DAIR was successful in only 35%
f these patients, while treatment success increased to 83% when
he implant was removed. These results were the same for hips
nd knees indicating that these joints can be approached the same.
owever, the causative microorganism and its susceptibility to an-
ibiotics should preferably be taken into account as well, as this
learly affected treatment outcome in our analysis; S. aureus was
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Fig. 3. Surgical flow chart to determine if a DAIR procedure is feasible or if implant removal should be performed as a first surgical approach. A DAIR procedure is recom- 
mended in the Figure when the failure rate of DAIR is ≤ 50%, implant removal is advised to be considered if the failure rate of DAIR is > 50%–65%, and implant removal is 
recommended when the failure rate of DAIR exceeds 65% in the studied subcategory. 
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s  an independent risk factor for failure in the multivariate analysis,
but treatment success was higher when a rifampin based antibiotic
regimen was administered. 
To decide which percentual a priori chance of failure is ac-
ceptable to still recommend a DAIR procedure as a first surgical
approach remains a matter of debate, and the advantages of a suc-
cessful DAIR should be balanced against the consequences of fail-
ure. In our study we advised revision surgery if the apriori chance
of DAIR failure exceeds more than 65%. It should be taken into
account that revision surgery is more aggressive, especially when
the implant is well fixed, and is associated with a higher economic
burden and longer hospital stay. 5,8 Although several studies indi-
cated that the success rate of revision surgery applied as salvage
therapy after a failed DAIR is very low (ranging between 35% and
58%), 9 , 12 , 18 these low success rates have not been confirmed by
others. 6 , 14 In our analysis, around 35% of patients who received
revision surgery after a failed DAIR procedure experienced pain at
the site of the implant during the last outpatient clinic visit, while
this was only 16% for those patients in whom revision surgery was
performed as a first approach. These results suggest that functional
outcome is worse when revision surgery is applied as salvage ther-
apy, but previous studies evaluating several validated functional
outcome scores do not support this finding. 7 , 12 Our results do not
indicate that applying revision surgery as first approach is not safe.
Although not statistical different, in patients with a CRIME80-score
≥ 3, mortality rate was even higher when patients were treated
with DAIR compared to implant removal (8.4% versus 4.2%). 
Our results should be interpreted in light of the following lim-
itations. One of the limitations of our study was the retrospective
study design with all the well-known limitations and risks for
bias. Although we performed 1:1 propensity matching to controlor bias, a randomized controlled trial remains the highest level of
vidence in demonstrating the superiority of one treatment over
nother. In spite of the fact that we did not observe any differ-
nces in comorbidity and age between both treatment groups,
e cannot completely rule out that a DAIR procedure was chosen
ased on the clinical judgment of the surgeon and therefore,
y definition performed in a selected group of patients with a
igher a priori chance to fail. Propensity score matching was only
erformed in a subset of patients that underwent DAIR (i.e. 24%
f the total cohort), imposing the risk that the severely ill patients
ere excluded from the propensity analysis (i.e. high fever, shorter
uration of symptoms), and a DAIR may still be the preferable
reatment option in an acute setting for these patients despite a
igh CRIME80 score. In addition, we do not have data whether the
mplant was fixed or loosened during revision surgery and/or an
steotomy was necessary to remove the implant. In general, DAIRs
re performed in fixed implants, and applying revision surgery in
hese cases, will lead to more bone destruction when removing
he implant compared to loosened prostheses. Although we did
ot find any differences in functional outcome after revision
urgery between cemented and uncemented protheses, the lack
f this information subjects our study to selection bias as well,
nd propensity matching cannot fully correct for this. Finally, the
utcome of DAIR is also determined by the antibiotic regimen
hat can be administered. In vivo animal models demonstrate the
fficacy of rifampin combinations in orthopaedic implant related
nfections in cases with a low bacterial inoculum and young
iofilm. 22 In particular the combination of rifampin with a fluoro-
uinolone has been proven to be a strong predictor of treatment
uccess in patients with staphylococcal PJI. 23 When choosing the
urgical strategy for late acute PJI, the causative microorganism
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nd is susceptibility to antibiotics is often not known, and thus,
his factor for predicting the chance of treatment success cannot
lways be taken into account. All of these limitations should be
aken into account when interpreting the results. 
In conclusion, DAIR is a viable treatment option in most pa-
ients with late acute PJI, but outcome is significantly worse com-
ared to implant removal. In patients with a high CRIME80-score
 ≥3) and in infections caused by S. aureus - in particular in those
n whom the mobile components cannot be exchanged and in
hom a rifampin-based regimen cannot be administered - revision
urgery should be considered. 
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